Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FA Clear all
Recruiting Phase 1 Interventional

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

NCT07180355
View directory record Official record
Conditions
Friedreich's Ataxia (FA)
Interventions
SGT-212
Drug
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Los Angeles, California • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

NCT07527975
View directory record Official record
Conditions
Fanconi Anemia
Interventions
RP-L102
Biological
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Salt-FA to Increase Folate Levels

NCT06174883
View directory record Official record
Conditions
Neural Tube Defects, Folic Acid Deficiency, Spina Bifida, Anencephaly-Spina Bifida
Interventions
Folic acid fortified iodized salt
Dietary Supplement
Lead sponsor
Hydrocephalus and Neuroscience Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 4, 2026, 10:04 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

NCT01884740
View directory record Official record
Conditions
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma, Pilomyxoid Astrocytoma, Mixed Oligodendroglioma-Astrocytoma, Brain Stem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
SIACI of Erbitux and Bevacizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 1 Interventional

Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia

NCT00272857
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Retrovirus Construct
Genetic
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 35 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 4, 2026, 10:04 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT05096663
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab
Dietary Supplement · Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
350
States / cities
Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 4, 2026, 10:04 AM EDT
Completed No phase listed Observational

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

NCT01644513
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
55 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 4, 2026, 10:04 AM EDT
Not listed Phase 1 Interventional

A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

NCT03814408
View directory record Official record
Conditions
Fanconi Anemia Complementation Group A
Interventions
RP-L102
Biological
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
1 Year to 12 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 4, 2026, 10:04 AM EDT
Recruiting No phase listed Observational

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

NCT06623890
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

NCT01452828
View directory record Official record
Conditions
Renal Impairment
Interventions
TR-701 FA single infusion, TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-Label, 10 Day Safety Study

NCT01623401
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 4, 2026, 10:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program

NCT06236100
View directory record Official record
Conditions
Substance-Related Disorders, Adverse Childhood Experiences
Interventions
Strengthening Families Program + Family Advocate, Strengthening Families Program
Behavioral
Lead sponsor
RTI International
Other
Eligibility
7 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tinton Falls, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems

NCT03716050
View directory record Official record
Conditions
Perfusion; Complications
Interventions
Nitroglycerin, Negative Pressure Wound Therapy/ Wound VAC, Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg), No treatment
Drug · Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Terminated No phase listed Observational

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

NCT01717937
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions
Phase variance optical coherence tomography (PV-OCT)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 4, 2026, 10:04 AM EDT
Recruiting No phase listed Observational

MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia Patients

NCT07649031
View directory record Official record
Conditions
Fanconi Anemia
Interventions
MRIs
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 1 Interventional

Cord Blood Plus Vitamin D and Omega 3s in T1D

NCT00873925
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Autologous UCB, Omega 3 FA, Vitamin D
Biological · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

NCT02928224
View directory record Official record
Conditions
BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions
Encorafenib, Binimetinib, Cetuximab, Irinotecan, Folinic Acid, 5-Fluorouracil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
90
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 4, 2026, 10:04 AM EDT
Enrolling by invitation No phase listed Observational

GABA and GSH in FRDA

NCT07635030
View directory record Official record
Conditions
Friedreich's Ataxia, FRDA
Interventions
MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug

NCT04299490
View directory record Official record
Conditions
Sleep Disorder, Healthy
Interventions
Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption, Undisturbed Sleep
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 48 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 4, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Chemoradiation or Brachytherapy for Rectal Cancer

NCT02017704
View directory record Official record
Conditions
Rectal Cancer
Interventions
Endo-HDR (if randomized to this arm), capecitabine and IMRT (if randomized to this arm), IMRT (intensity modulated radiation therapy), FOLFOX6, Surgery
Radiation · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 4, 2026, 10:04 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

NCT06054893
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 15 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 10:04 AM EDT
Recruiting Early Phase 1 Interventional

Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

NCT06123286
View directory record Official record
Conditions
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Interventions
Tart Cherry, Omega 3 FA (Fish Oil)
Drug
Lead sponsor
Philip Chang
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 4, 2026, 10:04 AM EDT